Global research-based biopharmaceutical company AbbVie has announced U.S FDA approval for their new therapy for adults with moderately to severely active rheumatoid arthritis (RA). RINVOQ is a once-daily (15mg) oral Janus kinase inhibitor supported by data from the SELECT program - one of the largest registrational Phase 3 programs in RA. Approximately 4,400 patients were evaluated across all treatment arms in five studies. The company says that RINVOQ has the potential to help additional people living with RA achieve remission who have not yet reached this goal. https://urlzs.com/SxYV2